U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

This week, they’re set to face intense scrutiny from ... underway testing an mRNA vaccine for HIV, a virus that has thwarted vaccinologists for decades. Moderna and Pfizer’s Covid-19 vaccines ...

Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE ... The panel voted 14-0 to recommend a single shot of both RSV vaccines for adults aged 50-59 who are ...

We continue to see obesity drugs and vaccines as areas of potential scrutiny ... which reinforce Pfizer’s wide moat. GSK, Pfizer, and Moderna: New RSV Vaccine Guidance Shrinks, but Long-Term ...

According to GSK, Pfizer’s RSV vaccine development began in 2013 ... making this a critical area for innovation and legal scrutiny.

And so has ABRYSVO, Pfizer's RSV vaccine, with large market share gains ... COVID-related sales for better long-term growth. So such scrutiny could put the managers and shareholders at risk ...

with Pfizer’s Abrysvo growing slightly faster at +29% w/w, whilst Moderna’s mRESVIA remains negligible,” Welford wrote. In RSV, Moderna’s attempt to overcome the challenges center on features that set ...